Mid-term results after drug eluting stenting of superficial femoral artery in critical limb ischemia patients. An Italian multicentre registry

Giuseppe Galzerano

Vascular and Endovascular Surgery Unit
Chief: Carlo Setacci
University of Siena
Siena - Italy
Disclosure

Speaker name:
Giuseppe Galzerano

I have the following potential conflicts of interest to report:

- Consulting
- Employment in industry
- Stockholder of a healthcare company
- Owner of a healthcare company
- Other(s)

I do not have any potential conflict of interest
SFA IS UNIQUE

1. Torsion
2. Extension / Contraction
3. Compression
4. Flexion
Z.O.R.R.O.

Zilver® PTX® Observational Registry on Recanalization for Obstructive disease
Aim of the study is to evaluate effectiveness of treatment using a drug eluting stent in superficial femoral artery and above the knee popliteal artery in patients suffering Critical Limb Ischemia. Even long lesions, up to 20 cm.
Inclusion criteria

- Patients suffering PAOD Ruth class ≥4
- "Reference Vessel Diameter" 4 - 9 mm
- Multi vessel diseases
Outcome

- 12 and 24 months patency
- Clinical success at 12 and 24 months
75 PATIENTS INCLUDED

12 ITALIAN VASCULAR SURGERIES

- SIENA, PROF. SETACCI: 15 CASES
- NAPOLI, DOTT. RUOTOLO: 15 CASES
- TRICASE, PROF. PALASCIANO: 8 CASES
- REGGIO EMILIA, DOTT. VECCHIATI: 8 CASES
- ROMA, PROF. SPEZIALE: 7 CASES
- ROMA, PROF. GOSSETTI: 4 CASES
- PALERMO, DOTT. TALARICO: 4 CASES
- NAPOLI, DOTT. MARESCA: 3 CASES
- GENOVA, DOTT. GORI: 3 CASES
- CATANIA, PROF. VEROUX: 2 CASES
- GENOVA, PROF. PALOMBO: 7 CASES
- BATTIPAGLIA, DOTT. CIMINO: 1 CASE
## DEMOGRAPHICS

<table>
<thead>
<tr>
<th>PATIENTS</th>
<th>75</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>MALE</td>
<td>54</td>
<td>72</td>
</tr>
<tr>
<td>DIABETES</td>
<td>37</td>
<td>49.3</td>
</tr>
<tr>
<td>HYPERTENSION</td>
<td>66</td>
<td>88</td>
</tr>
<tr>
<td>HYPERLIPIDEMIA</td>
<td>47</td>
<td>62.6</td>
</tr>
<tr>
<td>SMOKER</td>
<td>33</td>
<td>44</td>
</tr>
<tr>
<td>FORMER SMOKER</td>
<td>32</td>
<td>42.6</td>
</tr>
<tr>
<td>RENAL FAILURE</td>
<td>7</td>
<td>9.3</td>
</tr>
</tbody>
</table>
TASC CLASSIFICATION

- 36 rest pain
- 39 minor tissue loss
- 59 first treatment
- 16 redo
TECHNICAL NOTE

- **100% CORRECT DEPLOYMENT**
- 59 DE NOVO LESIONS
- 16 REDO PATIENTS

**AVERAGE LESION LENGTH:** 10.72 cm (1-33)
- 25 LESIONS > 15 CM

**NUMBER OF STENT FOR EACH PATIENT**

**RUN-OFF VESSELS**

**PRE OPERATIVE**

**POST OPERATIVE**
DUPLEX SCAN OUTCOMES

Primary patency 1 month: 96.0%

Primary Patency 6 months: 89.3%
Secondary Patency: 96%

Primary Patency 12 months: 84.8%
Secondary Patency: 95%

- 1 patients died
- 1 amputation
- 5 sec procedures
- 1+1 amputations
- 2 sec procedures
- No MAE
CUMULATIVE PATENCY

Cumulative Patency

Percent survival

days

0 200 400 600 800

84.9%

24 MONTHS ESTIMATED KM CURVE
CLINICAL OUTCOME

24 MONTHS ESTIMATED KM CURVE

amputation free survival

94.6%
PATENCY vs RUN OFF VESSELS

17/18 primary patency 94.4%

36/36 primary patency 100%

18/19 primary patency 94.7%

...AT 6 MONTHS FOLLOW-UP
CLINICAL CASE

- 3 ZILVER PTX 6/120mm

- PTA OF THE POPLITEAL ARTERY (Mustang 5/80mm)

- PTA TIBIO-PERONEAL TRUNK (Sterling 3X80mm)
Clinical outcome
CONCLUSIONS

• SFA BAD CONDUIT

• Zilver PTX is a safe and effective treatment for SFA in CLI

• Early and midterm patency / run off vessels
RINGRAZIAMENTI

Prof. Setacci SI
Dott. Ruotolo NA
Prof. Palasciano Tricase
Prof. Speziale RM
Dott. Vecchiati RE
Prof. Gossetti RM
Dott. Talarico PA
Dott. Crescenzi NA
Dott. Gori GE
Prof. Veroux CT
Prof. Palombo GE
Dott. Cimino Battipaglia
THANKS FOR THE ATTENTION
Mid-term results after drug eluting stenting of superficial femoral artery in critical limb ischemia patients. An Italian multicentre registry

Giuseppe Galzerano

Vascular and Endovascular Surgery Unit
Chief: Carlo Setacci
University of Siena
Siena - Italy